Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma. Dermatologic therapy Bagot, M., Dalle, S., Sokol, L., Tsianakas, A., Musiek, A., Ortiz-Romero, P. L., Poligone, B., Duvic, M., Elmets, C., Leoni, M., Dwyer, K., Ito, T., Herr, F., Kim, Y. H. 2022: e15634

View details for DOI 10.1111/dth.15634

View details for PubMedID 35695215